Among 13 analysts covering Brandywine Realty Trust (NYSE:BDN), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Brandywine Realty Trust had 38 analyst reports since August 14, 2015 according to SRatingsIntel. The stock of Brandywine Realty Trust (NYSE:BDN) has “Buy” rating given on Monday, October 23 by Stifel Nicolaus. The firm has “Equal-Weight” rating given on Friday, September 4 by Barclays Capital. The company was maintained on Tuesday, July 19 by Barclays Capital. The firm earned “Hold” rating on Friday, September 22 by KeyBanc Capital Markets. The firm earned “Hold” rating on Friday, September 4 by Zacks. The firm has “Hold” rating given on Friday, April 20 by Stifel Nicolaus. On Friday, July 15 the stock rating was downgraded by KeyBanc Capital Markets to “Underweight”. The stock of Brandywine Realty Trust (NYSE:BDN) earned “In-Line” rating by Evercore on Monday, May 15. The stock of Brandywine Realty Trust (NYSE:BDN) has “Buy” rating given on Wednesday, October 18 by SunTrust. Evercore upgraded the shares of BDN in report on Monday, December 19 to “Buy” rating. See Brandywine Realty Trust (NYSE:BDN) latest ratings:
24/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $18 New Target: $17 Maintain
23/04/2018 Broker: SunTrust Rating: Buy New Target: $18.0000 Maintain
23/04/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $17 New Target: $16 Maintain
20/04/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $16.0000 Maintain
16/04/2018 Broker: Barclays Capital Rating: Hold New Target: $17.0000
13/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Hold Old Target: $19 Downgrade
30/01/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $17 New Target: $18 Maintain
19/12/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $21.0 Upgrade
04/12/2017 Broker: Evercore Old Rating: In-Line New Rating: Outperform Upgrade
Essex Woodlands Health Ventures Inc decreased Revance Therapeutics Inc (RVNC) stake by 16.33% reported in 2017Q4 SEC filing. Essex Woodlands Health Ventures Inc sold 750,000 shares as Revance Therapeutics Inc (RVNC)’s stock declined 12.21%. The Essex Woodlands Health Ventures Inc holds 3.84 million shares with $137.35 million value, down from 4.59 million last quarter. Revance Therapeutics Inc now has $1.13 billion valuation. The stock increased 5.32% or $1.55 during the last trading session, reaching $30.7. About 192,262 shares traded. Revance Therapeutics, Inc. (NASDAQ:RVNC) has risen 51.24% since May 11, 2017 and is uptrending. It has outperformed by 39.69% the S&P500.
More notable recent Revance Therapeutics, Inc. (NASDAQ:RVNC) news were published by: Seekingalpha.com which released: “Your Daily Pharma Scoop: Abeona’s ABO-202, Revance Update, Ionis/Biogen’s New Collaboration” on April 23, 2018, also Globenewswire.com with their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Independent Bank Group, Eclipse Resources …” published on May 02, 2018, Businesswire.com published: “Revance Therapeutics Announces Two Recent Additions to Its Management Team” on May 09, 2018. More interesting news about Revance Therapeutics, Inc. (NASDAQ:RVNC) were released by: Cnbc.com and their article: “Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate …” published on May 01, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” with publication date: May 08, 2018.
Among 13 analysts covering Revance Therapeutics (NASDAQ:RVNC), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Revance Therapeutics had 30 analyst reports since August 22, 2015 according to SRatingsIntel. As per Tuesday, October 24, the company rating was maintained by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald on Wednesday, December 13 with “Buy”. Cantor Fitzgerald maintained the shares of RVNC in report on Thursday, November 2 with “Buy” rating. The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) earned “Hold” rating by Zacks on Saturday, August 22. Cantor Fitzgerald maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) rating on Thursday, April 12. Cantor Fitzgerald has “Buy” rating and $5000 target. On Tuesday, July 25 the stock rating was maintained by Piper Jaffray with “Buy”. The firm earned “Buy” rating on Tuesday, December 5 by Guggenheim. The firm has “Buy” rating given on Monday, November 23 by Guggenheim. The firm earned “Buy” rating on Wednesday, December 6 by Mizuho. Needham maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) rating on Monday, March 26. Needham has “Buy” rating and $4200 target.
Since March 7, 2018, it had 1 buying transaction, and 6 insider sales for $2.77 million activity. 3,150 shares were bought by Vickers Philip J., worth $98,393. SILVERNAIL LAUREN P sold $892,412 worth of Revance Therapeutics, Inc. (NASDAQ:RVNC) on Tuesday, March 13. 27,283 shares were sold by Browne L Daniel, worth $857,505 on Wednesday, March 7. 5,333 shares were sold by GARDNER PHYLLIS, worth $168,045.
Investors sentiment increased to 2.8 in 2017 Q4. Its up 1.80, from 1 in 2017Q3. It increased, as 6 investors sold RVNC shares while 19 reduced holdings. 31 funds opened positions while 39 raised stakes. 31.34 million shares or 15.17% more from 27.21 million shares in 2017Q3 were reported. Principal Gru Inc Inc has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 126,180 shares. Victory Capital Management reported 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC). Meeder Asset Mgmt owns 127 shares. Int accumulated 15,440 shares. Rhumbline Advisers owns 21,276 shares. Utd Automobile Association reported 78,560 shares. Manufacturers Life Insur Company The holds 0% or 18,172 shares in its portfolio. Millennium Mngmt Limited stated it has 1.10 million shares or 0.05% of all its holdings. Rhenman And Prtnrs Asset Mgmt Ab accumulated 182,580 shares. Jane Street Gru Inc Limited Liability Corp stated it has 19,172 shares or 0% of all its holdings. Winch Advisory Limited Co has invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Blackrock owns 2.17M shares. Qs Limited Liability Company invested in 68,459 shares or 0.02% of the stock. Quinn Opportunity Prtn Ltd Llc accumulated 0.05% or 9,100 shares. Canada Pension Plan Invest Board invested in 0.04% or 582,900 shares.
The stock decreased 1.76% or $0.295 during the last trading session, reaching $16.455. About 922,549 shares traded. Brandywine Realty Trust (NYSE:BDN) has declined 3.86% since May 11, 2017 and is downtrending. It has underperformed by 15.41% the S&P500.
Brandywine Realty Trust is a real estate investment trust. The company has market cap of $2.94 billion. The firm invests in real estate markets of the United States. It has a 25.32 P/E ratio. It provides leasing, property management, development, redevelopment, acquisition and other tenant-related services for a portfolio of office, residential, retail and mixed-use properties.
Another recent and important Brandywine Realty Trust (NYSE:BDN) news was published by Seekingalpha.com which published an article titled: “Brandywine: Patience Is A Virtue” on April 24, 2018.